GSK reviews drug promotion strategy
GlaxoSmithKline (GSK) is scrapping its incentive schemes following a corruption scandal in China.
The firm is reviewing the way new drugs are promoted and will stop paying doctors to promote its products through speaking engagements.
The company says the latest measures are unrelated to the Chinese investigation into alleged bribery.
Maryam Moshiri reports.
- From the section Business